Table 6– Summary of studies reporting nasal nitric oxide measurements with a portable nitric oxide analyser in PCD, healthy controls and cystic fibrosis patients, readings from a stationary analyser are shown for comparison if they were measured
StudyPCDHealthy controlsCystic fibrosis
StationaryPortableStationaryPortableStationaryPortable
Montella et al. [38], 2011#Median 1.5
(range 1.0–2.3),
n = 14
Median 2.6
(range 1.9–3.5),
n = 14
Median 13.7
(range 9.6–19.5),
n = 13
Median 12.4
(range 8.9–17.6),
n = 13
Median 9.5
(range 7.0–13.0),
n = 11
Median 13.4
(range 10.4–17.3),
n = 11
Harrison et al. [28], 2012Mean±sd 7.2±4.1,
n = 4
Mean±sd 125.7±22.8,
n = 5
Mean±sd 12±11.7,
n = 6
Marthin and Nielsen [17], 2013+Mean±sd 23.7±22.8,
n = 16
Mean±sd 19.2±18.7,
n = 12
Mean±sd 267±74.4,
n = 20
Mean±sd 180.9±57.7,
n = 21
Mean±sd 150.3±58.8,
n = 21
Mean±sd 97.2±41.6,
n = 8
Harris et al. [32], 2014§Median 12.3
(IQR 8.4),
n = 11
Median 5.4
(IQR 3.3),
n = 12
Median 208.2
(IQR 58.8),
n = 15
Median 112.6
(IQR 88.0),
n = 15
  • All nasal nitric oxide measurements have units of nL·min−1. PCD: primary ciliary dyskinesia; IQR: interquartile range. #: nasal exhalation; : tidal breathing; +: breath hold; §: tidal breathing (MINO Breathhold – Flex).